Thyrocare Technologies Limited (NSE:THYROCARE)
India
· Delayed Price · Currency is INR 889.35
-22.75 (-2.49%)
Apr 29, 2025, 2:30 PM IST
Thyrocare Technologies Revenue
In the fiscal year ending March 31, 2025, Thyrocare Technologies had annual revenue of 6.87B INR with 20.19% growth. Thyrocare Technologies had revenue of 1.74B in the quarter ending March 31, 2025, with 12.72% growth.
Revenue
6.87B
Revenue Growth
+20.19%
P/S Ratio
7.01
Revenue / Employee
4.06M
Employees
1,693
Market Cap
48.16B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 6.87B | 1.15B | 20.19% |
| Mar 31, 2024 | 5.72B | 452.10M | 8.58% |
| Mar 31, 2023 | 5.27B | -621.90M | -10.56% |
| Mar 31, 2022 | 5.89B | 942.40M | 19.05% |
| Mar 31, 2021 | 4.95B | 603.60M | 13.90% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 516.03B |
| Divi's Laboratories | 90.78B |
| Cipla | 267.20B |
| Mankind Pharma | 116.41B |
| Apollo Hospitals Enterprise | 211.46B |
| Zydus Lifesciences | 222.47B |
| Aurobindo Pharma | 309.22B |
| Alkem Laboratories | 127.57B |
Thyrocare Technologies News
- 5 days ago - Thyrocare Technologies Q4 results: Revenue up 21% YoY to Rs 187.2 crore, PAT jumps 88% YoY; Board recommends Rs 21 dividend per share - Business Upturn
- 3 months ago - Thyrocare Technologies Q3 FY25 Results: Revenue jumps 23.2% YoY to Rs 165.9 crore, Net Profit surges 24% YoY - Business Upturn